Barcelona patent court upholds valsartan-amlodipine patent invalidity

On 14 March 2018 the Barcelona Commercial Court Number 4 dismissed a patent infringement action brought by Novartis against the first generics in Spain of its valsartan and amlodipine medicinal product for the treatment of hypertension (Exforge). The court upheld the defendants’ counterclaim for invalidity of the asserted patent.